COSMO BIO COMPANY,LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 986 JPY | -0.50% |
|
-1.20% | +0.31% |
| Sales 2022 | 9.55B 60.89M | Sales 2023 | 9.34B 59.53M | Capitalization | 5.74B 36.56M |
|---|---|---|---|---|---|
| Net income 2022 | 517M 3.3M | Net income 2023 | 442M 2.82M | EV / Sales 2022 | 0.3 x |
| Net cash position 2022 | 3.02B 19.22M | Net cash position 2023 | 3B 19.15M | EV / Sales 2023 | 0.29 x |
| P/E ratio 2022 |
11.4
x | P/E ratio 2023 |
13
x | Employees | 155 |
| Yield 2022 |
3.56% | Yield 2023 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.50% | ||
| 1 week | -1.20% | ||
| Current month | -3.33% | ||
| 1 month | -3.80% | ||
| 3 months | -0.50% | ||
| 6 months | +1.23% | ||
| Current year | +0.31% |
1 week
985.00
997.00
1 month
985.001 039.00
Current year
940.001 072.00
1 year
937.001 072.00
3 years
937.001 282.00
5 years
695.001 412.00
10 years
695.002 649.00
| Managers | Title | Age | Since |
|---|---|---|---|
Masanori Hayashi
DFI | Director of Finance/CFO | - | - |
| President | 54 | 00-09-30 | |
| Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kazuya Shimamura
BRD | Director/Board Member | 51 | 14-02-28 |
| President | 54 | 00-09-30 | |
Junko Tochigi
BRD | Director/Board Member | 50 | 98-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 986 | -0.50% | 5 300 |
| 24-04-25 | 991 | -0.40% | 3,700 |
| 24-04-24 | 995 | +0.30% | 600 |
| 24-04-23 | 992 | +0.40% | 1,300 |
| 24-04-22 | 988 | -1.00% | 200 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes
COSMO BIO COMPANY,LIMITED is a Japan-based company mainly engaged in purchase and wholesale of research reagents, equipment, consignment services and clinical test drugs related to life science. Research reagents business imports majority research reagents from United States and Europe, which are prioritized in life science related research. In the equipment business, the Company handles equipment specialized in life science research, purchases goods from a wide range of domestic and overseas, and mainly sells it to the domestic market. The equipment includes ultrasonic cell disruption equipment, bioimaging related equipment and research consumables. The Company provides clinical test drugs mainly used at hospitals and testing centers.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +0.31% | 37.18M | |
| -23.45% | 1.44B | |
| -19.39% | 56.04M |
- Stock Market
- Equities
- 3386 Stock
